Drug Trial Radar · NCT03497897
Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne
Last checked: Nov 19, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Sep 10, 2018
Primary completion
Feb 24, 2022
Study completion Mar 9, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess preliminary efficacy and safety of LYS006 in patients with moderate to severe inflammatory acne and to determine if LYS006 has an adequate clinical profile for further clinical development.
Conditions
- Inflammatory Acne
Interventions
LYS006 20 mgDrug
LYS006 20 mg, capsules, oral administration, BID, for 12 weeks
LYS006 2 mgDrug
LYS006 2 mg, capsules, oral administration, BID, for 12 weeks
PlaceboDrug
Matching placebo, capsules, oral administration, BID, for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Inflammatory Lesion CountTime frame: Week 12
Locations
17 sites in 6 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Fremont, California
Novartis Investigative Site
Santa Monica, California
Novartis Investigative Site
Hialeah, Florida
Novartis Investigative Site
New Orleans, Louisiana
Novartis Investigative Site
Detroit, Michigan
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Pflugerville, Texas
Novartis Investigative Site
Pilsen, Czechia
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Bad Bentheim, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Szeged, Hungary
Novartis Investigative Site
Nijmegen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.